The focus of the Martin group is to understand the role of proteases and associated inhibitors in chronic airways diseases, such as CF and chronic obstructive pulmonary disease (COPD) and includes the profiling, delineation and inhibition of proteases involved in infection and inflammation. 

In particular, the targeting of channel activating proteases (CAPs) as a means to regulate the epithelial sodium channel (ENaC), dysregulation of which contributes to airways dehydration, has now progressed to include an important drug discovery/development element.